Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft Versus-host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation

NCT05166967 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT05166967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05166967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft Versus-host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2022
Completion date
July 29, 2025
Enrollment
204 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haploidentical hematopoietic stem cell transplantation